Royalty Pharma plc (RPRX)
After hours:
| Previous close | 39.74 |
| Open | 39.49 |
| Bid | 39.34 x 3200 |
| Ask | 40.94 x 4000 |
| Day's range | 39.36 - 40.32 |
| 52-week range | 34.86 - 47.10 |
| Volume | |
| Avg. volume | 2,130,401 |
| Market cap | 27.108B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 29.37 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.76 (1.90%) |
| Ex-dividend date | 19 May 2022 |
| 1y target est | N/A |
- GlobeNewswire
Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical roya
- GlobeNewswire
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected to grow 10% or more over this decade, positioning Royalty Pharma to be one of the fastest growing biopharma companiesDemand for capital to fund life sciences innovation to exceed $1 trillion in next decade NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host its ina
- GlobeNewswire
Royalty Pharma Reports First Quarter 2022 Results
Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed: Adjusted Cash Receipts(1) expected to be $2,225 to $2,300 million NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial mea
